Xenoport, Inc. (XNPT)
-NasdaqGS 5.78 
0.39(7.24%) 4:00PM EDT|After Hours
:
5.39 0.39 (6.75%) 5:00PM EDT
| Prev Close: | 5.39 |
|---|
| Open: | 5.49 |
|---|
| Bid: | 5.48 x 1200 |
|---|
| Ask: | 5.77 x 200 |
|---|
| 1y Target Est: | 8.57 |
|---|
| Beta: | 0.63 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 5.45 - 5.83 |
|---|
| 52wk Range: | 5.00 - 12.98 |
|---|
| Volume: | 715,312 |
|---|
| Avg Vol (3m): | 491,060 |
|---|
| Market Cap: | 273.98M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Xenoport Director Buys 20K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Fri 12:22PM EDT)
- XENOPORT INC Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 23)
- XenoPort Resumes Horizant SupplyZacks(Wed, May 22)
- XenoPort Candidate DisappointsZacks(Tue, May 21)
- XenoPort weakness creates buying opportunity, says Wells Fargoat theflyonthewall.com(Tue, May 21)
- XenoPort's CEO Presents at Special Conference (Transcript)at Seeking Alpha(Mon, May 20)
- Why XenoPort Shares Stumbledat Motley Fool(Mon, May 20)
- XenoPort MS treatment fails in late-stage testingAP(Mon, May 20)
- XenoPort Sinks as Spasticity Drug For MS Fails in Trialat Bloomberg(Mon, May 20)
- Websense rockets on $1 billion LBOoptionMONSTER(Mon, May 20)
- XenoPort to drop multiple sclerosis drug after trial failureat Reuters(Mon, May 20)
- XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis PatientsBusiness Wire(Mon, May 20)
- XenoPort: Horizant likely available in early JuneAP(Fri, May 17)
- XenoPort Provides Update on Availability of HorizantBusiness Wire(Fri, May 17)
- XENOPORT INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 21.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.02 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.54 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -0.53 |
|---|
Business Summary
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders.
View More